PTC Therapeutics (PTCT)
PTC Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
8.3M
Short interest
settlement 2026-10-15
7.6
Days to cover
+1.5 days vs prior
43.7%
Short share of volume
2026-10-28
688
Fails to deliver
settlement 2026-09-21
Tue 3 Nov
Next earnings
estimated date
-$8.5M
Insider flow, 90 days
0 buys, 27 sells
As of 2026-10-28.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in PTCT is 8,303,282 shares, down 1,435,637 shares over the last month. Over the last 48 readings it ranged from 3,696,224 shares (14 February 2025) to 17,315,032 shares (30 June 2026). At the reported average volume of 1.1M shares a day that is 7.6 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/ptct" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 8,303,282 | -9.4% | 1,094,576 | 7.59 |
| 2026-09-30 | 9,168,333 | -5.9% | 1,493,955 | 6.14 |
| 2026-09-15 | 9,738,919 | -0.9% | 882,762 | 11.03 |
| 2026-08-31 | 9,828,154 | -3.8% | 809,909 | 12.13 |
| 2026-08-14 | 10,221,046 | -3.3% | 944,361 | 10.82 |
| 2026-07-31 | 10,566,249 | +7.5% | 1,404,384 | 7.52 |
| 2026-07-15 | 9,833,980 | -43.2% | 2,069,373 | 4.75 |
| 2026-06-30 | 17,315,032 | +46.9% | 3,228,848 | 5.36 |
| 2026-06-15 | 11,783,786 | +10.4% | 1,505,935 | 7.82 |
| 2026-05-29 | 10,674,185 | +4.2% | 963,231 | 11.08 |
| 2026-05-15 | 10,240,784 | +5.0% | 1,708,791 | 5.99 |
| 2026-04-30 | 9,756,300 | +14.1% | 1,311,465 | 7.44 |
| 2026-04-15 | 8,547,862 | -9.6% | 805,907 | 10.61 |
| 2026-03-31 | 9,452,081 | +6.8% | 1,123,937 | 8.41 |
| 2026-03-13 | 8,847,565 | -8.0% | 1,270,671 | 6.96 |
| 2026-02-27 | 9,616,593 | +0.3% | 1,183,440 | 8.13 |
| 2026-02-13 | 9,591,953 | -4.9% | 1,067,536 | 8.99 |
| 2026-01-30 | 10,081,569 | -2.0% | 1,077,954 | 9.35 |
| 2026-01-15 | 10,290,419 | -3.9% | 1,648,405 | 6.24 |
| 2025-12-31 | 10,709,685 | -6.4% | 1,068,070 | 10.03 |
| 2025-12-15 | 11,442,932 | -11.0% | 1,517,596 | 7.54 |
| 2025-11-28 | 12,859,294 | +36.5% | 3,134,304 | 4.10 |
| 2025-11-14 | 9,418,915 | +13.0% | 1,485,598 | 6.34 |
| 2025-10-31 | 8,337,064 | +6.7% | 837,044 | 9.96 |
| 2025-10-15 | 7,816,416 | +9.5% | 1,222,340 | 6.39 |
| 2025-09-30 | 7,136,920 | -2.1% | 1,227,824 | 5.81 |
| 2025-09-15 | 7,292,929 | +9.8% | 1,514,531 | 4.82 |
| 2025-08-29 | 6,643,065 | +2.3% | 1,182,530 | 5.62 |
| 2025-08-15 | 6,496,742 | +8.0% | 1,282,734 | 5.06 |
| 2025-07-31 | 6,016,226 | +4.2% | 1,193,510 | 5.04 |
| 2025-07-15 | 5,772,442 | -3.7% | 1,045,209 | 5.52 |
| 2025-06-30 | 5,996,119 | +18.2% | 1,274,776 | 4.70 |
| 2025-06-13 | 5,072,028 | +6.7% | 959,389 | 5.29 |
| 2025-05-30 | 4,751,620 | -8.0% | 896,921 | 5.30 |
| 2025-05-15 | 5,165,514 | +3.2% | 2,154,643 | 2.40 |
| 2025-04-30 | 5,006,670 | -8.6% | 864,022 | 5.79 |
| 2025-04-15 | 5,479,034 | +1.1% | 1,455,076 | 3.77 |
| 2025-03-31 | 5,418,328 | +25.9% | 842,802 | 6.43 |
| 2025-03-14 | 4,302,958 | +13.6% | 917,404 | 4.69 |
| 2025-02-28 | 3,789,596 | +2.5% | 753,498 | 5.03 |
| 2025-02-14 | 3,696,224 | -11.2% | 858,061 | 4.31 |
| 2025-01-31 | 4,161,584 | -1.9% | 632,430 | 6.58 |
| 2025-01-15 | 4,240,687 | +0.9% | 582,829 | 7.28 |
| 2024-12-31 | 4,201,416 | -8.5% | 530,159 | 7.92 |
| 2024-12-13 | 4,590,192 | -0.1% | 1,046,300 | 4.39 |
| 2024-11-29 | 4,596,593 | -1.6% | 727,228 | 6.32 |
| 2024-11-15 | 4,673,031 | -4.4% | 757,083 | 6.17 |
| 2024-10-31 | 4,886,780 | +4.9% | 755,009 | 6.47 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 28 October 2026, the short share of PTCT volume is 43.7%, down 18.9 points over the last five sessions. Over the last 30 readings it ranged from 26.7% (27 October 2026) to 67.4% (17 September 2026). The latest reading is 2.7 points below the 30-session average of 46.4%, on 341K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-28 | 149K | 341K | 43.7% | 12 |
| 2026-10-27 | 134K | 504K | 26.7% | 0 |
| 2026-10-26 | 141K | 305K | 46.3% | 0 |
| 2026-10-23 | 144K | 225K | 63.8% | 2 |
| 2026-10-22 | 167K | 262K | 63.6% | 61 |
| 2026-10-21 | 149K | 239K | 62.6% | 0 |
| 2026-10-20 | 151K | 309K | 49.1% | 0 |
| 2026-10-19 | 127K | 379K | 33.6% | 0 |
| 2026-10-16 | 183K | 284K | 64.5% | 0 |
| 2026-10-15 | 180K | 344K | 52.4% | 0 |
| 2026-10-14 | 250K | 662K | 37.7% | 0 |
| 2026-10-13 | 125K | 341K | 36.7% | 0 |
| 2026-10-12 | 146K | 264K | 55.2% | 0 |
| 2026-10-09 | 248K | 611K | 40.5% | 0 |
| 2026-10-08 | 353K | 577K | 61.2% | 0 |
| 2026-10-07 | 113K | 418K | 27.1% | 0 |
| 2026-10-06 | 173K | 375K | 46.2% | 0 |
| 2026-10-05 | 152K | 389K | 38.9% | 898 |
| 2026-10-02 | 136K | 388K | 35.1% | 0 |
| 2026-10-01 | 246K | 449K | 54.7% | 0 |
| 2026-09-30 | 110K | 264K | 41.7% | 0 |
| 2026-09-29 | 196K | 368K | 53.1% | 0 |
| 2026-09-28 | 234K | 827K | 28.3% | 0 |
| 2026-09-25 | 225K | 500K | 45.1% | 0 |
| 2026-09-24 | 225K | 699K | 32.1% | 0 |
| 2026-09-23 | 215K | 386K | 55.7% | 0 |
| 2026-09-22 | 169K | 497K | 34.1% | 0 |
| 2026-09-21 | 185K | 424K | 43.6% | 0 |
| 2026-09-18 | 175K | 331K | 52.8% | 207 |
| 2026-09-17 | 325K | 482K | 67.4% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 21 September 2026, the fails-to-deliver balance in PTCT is 688 shares, up 666 shares over the last settlement date. Over the last 30 readings it ranged from 7 shares (27 April 2026) to 375,002 shares (28 July 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-21 | 688 | $65.37 | $45K |
| 2026-09-11 | 22 | $67.37 | $1K |
| 2026-08-17 | 15,042 | $71.70 | $1.1M |
| 2026-08-12 | 2,757 | $73.70 | $203K |
| 2026-08-11 | 46,848 | $74.63 | $3.5M |
| 2026-08-04 | 18 | $68.12 | $1K |
| 2026-08-03 | 27 | $68.01 | $2K |
| 2026-07-29 | 39 | $75.39 | $3K |
| 2026-07-28 | 375,002 | $75.80 | $28.4M |
| 2026-07-17 | 636 | $78.52 | $50K |
| 2026-07-08 | 29,124 | $89.20 | $2.6M |
| 2026-06-30 | 124,368 | $81.57 | $10.1M |
| 2026-06-26 | 11 | $84.51 | $930 |
| 2026-06-22 | 10 | $78.98 | $790 |
| 2026-06-17 | 7,985 | $73.27 | $585K |
| 2026-06-12 | 7 | $74.71 | $523 |
| 2026-06-04 | 1,281 | $68.68 | $88K |
| 2026-06-01 | 2,392 | $73.85 | $177K |
| 2026-05-26 | 745 | $68.81 | $51K |
| 2026-05-22 | 7 | $69.79 | $489 |
| 2026-05-20 | 864 | $70.31 | $61K |
| 2026-05-14 | 7 | $73.46 | $514 |
| 2026-05-08 | 11,393 | $64.49 | $735K |
| 2026-05-06 | 235 | $65.04 | $15K |
| 2026-04-29 | 71 | $70.26 | $5K |
| 2026-04-27 | 7 | $68.23 | $478 |
| 2026-04-21 | 2,218 | $72.32 | $160K |
| 2026-04-20 | 42 | $72.43 | $3K |
| 2026-04-13 | 1,900 | $68.69 | $131K |
| 2026-04-09 | 48,960 | $71.26 | $3.5M |
Insider trades
SEC Form 4, newest first. JSONInsiders at PTCT reported 27 open-market sells worth $8.5M in the last 90 days and no open-market buys. Latest filing: SCHMERTZLER MICHAEL (Director) on 2026-10-14.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-14 | SCHMERTZLER MICHAEL | Director | Sell | 382 | $60.14 | $23K | 1.3M |
| 2026-10-14 | SCHMERTZLER MICHAEL | Director | Sell | 2K | $59.52 | $126K | 1.3M |
| 2026-10-09 | Boulding Mark Elliott | EXEC. VP AND CLO | Sell | 192 | $64.26 | $12K | 105K |
| 2026-10-09 | Boulding Mark Elliott | EXEC. VP AND CLO | Exercise or conversion | 192 | $39.42 | $8K | 105K |
| 2026-10-07 | SCHMERTZLER MICHAEL | Director | Sell | 53 | $63.95 | $3K | 1.3M |
| 2026-10-07 | SCHMERTZLER MICHAEL | Director | Sell | 2K | $63.38 | $155K | 1.3M |
| 2026-10-06 | Boulding Mark Elliott | EXEC. VP AND CLO | Sell | 435 | $64.16 | $28K | 105K |
| 2026-10-06 | Boulding Mark Elliott | EXEC. VP AND CLO | Exercise or conversion | 435 | $39.42 | $17K | 106K |
| 2026-10-05 | Boulding Mark Elliott | EXEC. VP AND CLO | Sell | 2K | $64.03 | $105K | 105K |
| 2026-10-05 | Boulding Mark Elliott | EXEC. VP AND CLO | Exercise or conversion | 2K | $39.42 | $65K | 107K |
| 2026-09-30 | STEELE GLENN JR MD PHD | Director | Sell | 12K | $65.16 | $782K | 23K |
| 2026-09-30 | STEELE GLENN JR MD PHD | Director | Exercise or conversion | 12K | $11.23 | $135K | 35K |
| 2026-09-17 | SCHMERTZLER MICHAEL | Director | Sell | 376 | $68.45 | $26K | 1.3M |
| 2026-09-17 | SCHMERTZLER MICHAEL | Director | Sell | 10K | $67.83 | $653K | 1.3M |
| 2026-09-16 | SCHMERTZLER MICHAEL | Director | Sell | 7K | $67.35 | $472K | 1.3M |
| 2026-09-16 | SCHMERTZLER MICHAEL | Director | Sell | 3K | $66.58 | $199K | 1.3M |
| 2026-09-10 | SCHMERTZLER MICHAEL | Director | Sell | 10K | $67.34 | $673K | 1.3M |
| 2026-09-09 | SCHMERTZLER MICHAEL | Director | Sell | 572 | $68.67 | $39K | 1.3M |
| 2026-09-09 | SCHMERTZLER MICHAEL | Director | Sell | 9K | $67.79 | $639K | 1.3M |
| 2026-08-27 | SCHMERTZLER MICHAEL | Director | Sell | 610 | $72.22 | $44K | 1.3M |
| 2026-08-27 | SCHMERTZLER MICHAEL | Director | Sell | 12K | $71.55 | $851K | 1.3M |
| 2026-08-26 | SCHMERTZLER MICHAEL | Director | Sell | 6K | $73.18 | $412K | 1.3M |
| 2026-08-26 | SCHMERTZLER MICHAEL | Director | Sell | 7K | $72.74 | $500K | 1.4M |
| 2026-08-20 | SCHMERTZLER MICHAEL | Director | Sell | 691 | $72.92 | $50K | 1.4M |
| 2026-08-20 | SCHMERTZLER MICHAEL | Director | Sell | 2K | $71.88 | $172K | 1.4M |
| 2026-08-20 | SCHMERTZLER MICHAEL | Director | Sell | 9K | $70.78 | $667K | 1.4M |
| 2026-08-19 | SCHMERTZLER MICHAEL | Director | Sell | 7K | $73.67 | $528K | 1.4M |
| 2026-08-19 | SCHMERTZLER MICHAEL | Director | Sell | 5K | $72.86 | $389K | 1.4M |
| 2026-08-17 | Boulding Mark Elliott | EXEC. VP AND CLO | Sell | 969 | $72.90 | $71K | 105K |
| 2026-08-17 | Boulding Mark Elliott | EXEC. VP AND CLO | Sell | 2K | $72.39 | $133K | 106K |
| 2026-08-17 | Boulding Mark Elliott | EXEC. VP AND CLO | Exercise or conversion | 3K | $25.69 | $72K | 108K |
| 2026-08-04 | Klein Matthew B. | CHIEF EXECUTIVE OFFICER | Sell | 10K | $68.57 | $706K | 384K |
| 2026-07-28 | Sollie-Zetlmayer Hege Elisabeth | Director | Grant | 2K | $0.00 | $0 | 53K |
| 2026-07-28 | Sollie-Zetlmayer Hege Elisabeth | Director | Grant | 4K | $0.00 | $0 | 51K |
| 2026-07-14 | Gravier Pierre | CHIEF FINANCIAL OFFICER | Sell | 3K | $80.35 | $281K | 84K |
| 2026-07-09 | Smith Mary L. | Director | Sell | 6K | $90.00 | $525K | 22K |
| 2026-07-09 | Smith Mary L. | Director | Exercise or conversion | 6K | $42.95 | $251K | 28K |
| 2026-07-09 | Smith Mary L. | Director | Sell | 10K | $90.00 | $900K | 22K |
| 2026-07-09 | Smith Mary L. | Director | Exercise or conversion | 10K | $42.95 | $430K | 32K |
| 2026-07-09 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Sell | 2K | $90.25 | $222K | 60K |
| 2026-07-09 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Exercise or conversion | 2K | $46.54 | $115K | 63K |
| 2026-07-07 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Sell | 9K | $89.44 | $831K | 60K |
| 2026-07-07 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Sell | 11K | $89.03 | $1.0M | 70K |
| 2026-07-07 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Sell | 4K | $87.17 | $345K | 81K |
| 2026-07-07 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Exercise or conversion | 25K | $39.42 | $970K | 85K |
| 2026-07-06 | Boulding Mark Elliott | EXEC. VP AND CLO | Sell | 745 | $86.38 | $64K | 105K |
| 2026-07-06 | Boulding Mark Elliott | EXEC. VP AND CLO | Sell | 645 | $85.84 | $55K | 106K |
| 2026-07-06 | Boulding Mark Elliott | EXEC. VP AND CLO | Sell | 1K | $84.41 | $87K | 107K |
| 2026-07-06 | Boulding Mark Elliott | EXEC. VP AND CLO | Sell | 387 | $83.10 | $32K | 108K |
| 2026-07-06 | Boulding Mark Elliott | EXEC. VP AND CLO | Exercise or conversion | 3K | $46.54 | $131K | 108K |
| 2026-07-06 | Boulding Mark Elliott | EXEC. VP AND CLO | Sell | 601 | $86.38 | $52K | 105K |
| 2026-07-06 | Boulding Mark Elliott | EXEC. VP AND CLO | Sell | 519 | $85.84 | $45K | 106K |
| 2026-07-06 | Boulding Mark Elliott | EXEC. VP AND CLO | Sell | 833 | $84.41 | $70K | 106K |
| 2026-07-06 | Boulding Mark Elliott | EXEC. VP AND CLO | Sell | 313 | $83.10 | $26K | 107K |
| 2026-07-06 | Boulding Mark Elliott | EXEC. VP AND CLO | Exercise or conversion | 2K | $39.42 | $89K | 108K |
| 2026-07-06 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Sell | 2K | $87.03 | $215K | 60K |
| 2026-07-06 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Exercise or conversion | 2K | $39.42 | $98K | 63K |
| 2026-07-06 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Sell | 10K | $86.32 | $871K | 60K |
| 2026-07-06 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Sell | 9K | $85.35 | $750K | 70K |
| 2026-07-06 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Exercise or conversion | 19K | $38.10 | $719K | 79K |
| 2026-07-06 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Sell | 385 | $86.34 | $33K | 60K |
| 2026-07-06 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Sell | 426 | $85.28 | $36K | 61K |
| 2026-07-06 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Exercise or conversion | 811 | $38.10 | $31K | 61K |
| 2026-06-26 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Sell | 8K | $85.26 | $658K | 60K |
| 2026-06-26 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Exercise or conversion | 8K | $38.10 | $294K | 68K |
| 2026-06-26 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Sell | 412 | $85.23 | $35K | 60K |
| 2026-06-26 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Exercise or conversion | 412 | $38.10 | $16K | 61K |
| 2026-06-25 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Sell | 100 | $87.00 | $9K | 60K |
| 2026-06-25 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Exercise or conversion | 100 | $39.42 | $4K | 60K |
| 2026-06-25 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Sell | 11K | $86.51 | $981K | 60K |
| 2026-06-25 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Sell | 9K | $85.26 | $727K | 71K |
| 2026-06-25 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Exercise or conversion | 20K | $38.10 | $757K | 80K |
| 2026-06-25 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Sell | 419 | $86.39 | $36K | 60K |
| 2026-06-25 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Sell | 582 | $85.24 | $50K | 61K |
| 2026-06-25 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Exercise or conversion | 1K | $38.10 | $38K | 61K |
| 2026-06-24 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Sell | 5K | $85.03 | $419K | 60K |
| 2026-06-24 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Exercise or conversion | 5K | $38.10 | $188K | 65K |
| 2026-06-24 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Sell | 401 | $85.01 | $34K | 60K |
| 2026-06-24 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Exercise or conversion | 401 | $38.10 | $15K | 61K |
| 2026-06-22 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Sell | 12K | $81.21 | $944K | 60K |
| 2026-06-22 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Sell | 12K | $80.61 | $978K | 72K |
| 2026-06-22 | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Exercise or conversion | 24K | $25.69 | $610K | 84K |
| 2026-06-17 | Boulding Mark Elliott | EXEC. VP AND CLO | Sell | 7K | $78.50 | $518K | 107K |
| 2026-06-17 | Boulding Mark Elliott | EXEC. VP AND CLO | Exercise or conversion | 9K | $46.54 | $396K | 114K |
| 2026-06-17 | Boulding Mark Elliott | EXEC. VP AND CLO | Sell | 309 | $79.25 | $24K | 105K |
| 2026-06-17 | Boulding Mark Elliott | EXEC. VP AND CLO | Sell | 2K | $78.50 | $134K | 106K |
| 2026-06-17 | Boulding Mark Elliott | EXEC. VP AND CLO | Exercise or conversion | 2K | $46.54 | $94K | 107K |
| 2026-06-17 | Boulding Mark Elliott | EXEC. VP AND CLO | Sell | 2K | $79.24 | $147K | 105K |
| 2026-06-17 | Utter Christine Marie | SVP, CHIEF ACCOUNTING OFFICER | Sell | 20K | $75.56 | $1.5M | 70K |
| 2026-06-17 | Utter Christine Marie | SVP, CHIEF ACCOUNTING OFFICER | Exercise or conversion | 20K | $25.69 | $506K | 90K |
| 2026-06-10 | Pauwels Eric | CHIEF BUSINESS OFFICER | Exercise or conversion | 18K | $18.01 | $316K | 91K |
| 2026-06-10 | Pauwels Eric | CHIEF BUSINESS OFFICER | Sell | 18K | $75.00 | $1.3M | 73K |
| 2026-06-10 | Pauwels Eric | CHIEF BUSINESS OFFICER | Sell | 4K | $75.00 | $278K | 73K |
| 2026-05-15 | Boulding Mark Elliott | EXEC. VP AND CLO | Sell | 456 | $72.67 | $33K | 105K |
| 2026-05-15 | Boulding Mark Elliott | EXEC. VP AND CLO | Sell | 2K | $72.08 | $170K | 106K |
| 2026-05-15 | Boulding Mark Elliott | EXEC. VP AND CLO | Exercise or conversion | 3K | $25.69 | $72K | 108K |
| 2026-05-14 | Klein Matthew B. | CHIEF EXECUTIVE OFFICER | Sell | 3K | $72.46 | $186K | 394K |
| 2026-05-14 | Klein Matthew B. | CHIEF EXECUTIVE OFFICER | Sell | 2K | $73.08 | $153K | 397K |
| 2026-05-14 | Klein Matthew B. | CHIEF EXECUTIVE OFFICER | Sell | 7K | $73.08 | $528K | 399K |
| 2026-05-14 | Klein Matthew B. | CHIEF EXECUTIVE OFFICER | Sell | 679 | $73.06 | $50K | 406K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON50 Form 144 notices on file for PTCT worth $28.3M at the prices reported; 6 in the last 90 days worth $1.8M. Latest: Boulding Mark Elliott filed on 2026-10-09 to sell 192 shares ($12K) from 2026-10-09.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-10-09 | Boulding Mark ElliottOfficer | 192 | $12K | 0.000% | 2026-10-09 | Fidelity Brokerage Services LLC |
| 2026-10-06 | Boulding Mark ElliottOfficer | 435 | $28K | 0.001% | 2026-10-06 | Fidelity Brokerage Services LLC |
| 2026-10-05 | Boulding Mark ElliottOfficer | 2K | $105K | 0.002% | 2026-10-05 | Fidelity Brokerage Services LLC |
| 2026-09-30 | STEELE GLENN JR MD PHDDirector | 12K | $782K | 0.014% | 2026-09-30 | Fidelity Brokerage Services LLC |
| 2026-08-17 | Boulding Mark ElliottOfficer | 3K | $202K | 0.003% | 2026-08-17 | Fidelity Brokerage Services LLC |
| 2026-08-04 | Klein Matthew B.Officer, Director | 10K | $706K | 0.012% | 2026-08-04 | Fidelity Brokerage Services LLC |
| 2026-07-14 | Gravier PierreOfficer | 3K | $281K | 0.004% | 2026-07-14 | Fidelity Brokerage Services LLC |
| 2026-07-09 | Smith Mary L.Director | 16K | $1.4M | 0.019% | 2026-07-09 | Fidelity Brokerage Services LLC |
| 2026-07-09 | Almstead Neil GregoryOfficer | 2K | $222K | 0.003% | 2026-07-09 | Fidelity Brokerage Services LLC |
| 2026-07-07 | Almstead Neil GregoryOfficer | 25K | $2.2M | 0.030% | 2026-07-07 | Fidelity Brokerage Services LLC |
| 2026-07-06 | Boulding Mark ElliottOfficer | 5K | $427K | 0.006% | 2026-07-06 | Fidelity Brokerage Services LLC |
| 2026-07-06 | Almstead Neil GregoryOfficer | 22K | $1.9M | 0.027% | 2026-07-06 | Fidelity Brokerage Services LLC |
| 2026-06-26 | Almstead Neil GregoryOfficer | 8K | $693K | 0.010% | 2026-06-26 | Fidelity Brokerage Services LLC |
| 2026-06-25 | Almstead Neil GregoryOfficer | 21K | $1.8M | 0.025% | 2026-06-25 | Fidelity Brokerage Services LLC |
| 2026-06-24 | Almstead Neil GregoryOfficer | 5K | $453K | 0.006% | 2026-06-24 | Fidelity Brokerage Services LLC |
| 2026-06-22 | Almstead Neil GregoryOfficer | 24K | $1.9M | 0.029% | 2026-06-22 | Fidelity Brokerage Services LLC |
| 2026-06-17 | Utter Christine MarieOfficer | 20K | $1.5M | 0.024% | 2026-06-17 | Fidelity Brokerage Services LLC |
| 2026-06-17 | Boulding Mark ElliottOfficer | 11K | $828K | 0.013% | 2026-06-17 | Fidelity Brokerage Services LLC |
| 2026-06-10 | Pauwels EricOfficer | 21K | $1.6M | 0.026% | 2026-06-10 | Fidelity Brokerage Services LLC |
| 2026-05-15 | Boulding Mark ElliottOfficer | 3K | $204K | 0.003% | 2026-05-15 | Fidelity Brokerage Services LLC |
| 2026-05-14 | Klein Matthew B.Officer, Director | 3K | $186K | 0.003% | 2026-05-14 | Fidelity Brokerage Services LLC |
| 2026-05-14 | Klein Matthew B.Officer, Director | 10K | $731K | 0.012% | 2026-05-14 | Fidelity Brokerage Services LLC |
| 2026-05-08 | Boulding Mark ElliottOfficer | 4K | $280K | 0.004% | 2026-05-08 | Fidelity Brokerage Services LLC |
| 2026-04-21 | Klein Matthew B.Officer, Director | 3K | $202K | 0.003% | 2026-04-21 | Fidelity Brokerage Services LLC |
| 2026-04-06 | Boulding Mark ElliottOfficer | 2K | $157K | 0.003% | 2026-04-06 | Fidelity Brokerage Services LLC |
| 2026-04-02 | Golden Lee ScottOfficer | 829 | $56K | 0.001% | 2026-04-02 | Fidelity Brokerage Services LLC |
| 2026-04-01 | Almstead Neil GregoryOfficer | 52K | $3.6M | 0.063% | 2026-04-01 | Fidelity Brokerage Services LLC |
| 2026-03-12 | Klein Matthew B.Officer, Director | 3K | $171K | 0.003% | 2026-03-12 | Fidelity Brokerage Services LLC |
| 2026-03-10 | Okey StephanieDirector | 15K | $1.1M | 0.018% | 2026-03-10 | Fidelity Brokerage Services LLC |
| 2026-03-05 | Okey StephanieDirector | 6K | $401K | 0.008% | 2026-03-05 | Fidelity Brokerage Services LLC |
| 2026-03-05 | Golden Lee ScottOfficer | 10K | $634K | 0.012% | 2026-03-05 | Fidelity Brokerage Services LLC |
| 2026-03-05 | Almstead Zheng YangMember of immediate family of any of the foregoing | 4K | $253K | 0.005% | 2026-03-05 | Fidelity Brokerage Services LLC |
| 2026-02-19 | Boulding Mark ElliottOfficer | 3K | $207K | 0.004% | 2026-02-19 | Fidelity Brokerage Services LLC |
| 2026-02-18 | Pauwels EricOfficer | 3K | $209K | 0.004% | 2026-02-18 | Fidelity Brokerage Services LLC |
| 2026-02-18 | Utter Christine MarieOfficer | 2K | $173K | 0.003% | 2026-02-18 | Fidelity Brokerage Services LLC |
| 2026-02-18 | Klein Matthew B.Officer, Director | 7K | $511K | 0.009% | 2026-02-18 | Fidelity Brokerage Services LLC |
| 2026-02-18 | Gravier PierreOfficer | 3K | $208K | 0.004% | 2026-02-18 | Fidelity Brokerage Services LLC |
| 2026-02-18 | Golden Lee ScottOfficer | 2K | $172K | 0.003% | 2026-02-18 | Fidelity Brokerage Services LLC |
| 2026-02-18 | Boulding Mark ElliottOfficer | 3K | $214K | 0.004% | 2026-02-18 | Fidelity Brokerage Services LLC |
| 2026-02-18 | Almstead Zheng YangMember of immediate family of any of the foregoing | 65 | $5K | 0.000% | 2026-02-18 | Fidelity Brokerage Services LLC |
| 2026-02-18 | Almstead Neil GregoryOfficer | 3K | $212K | 0.004% | 2026-02-18 | Fidelity Brokerage Services LLC |
| 2026-02-17 | Boulding Mark ElliottOfficer | 3K | $194K | 0.004% | 2026-02-17 | Fidelity Brokerage Services LLC |
| 2026-01-09 | Pauwels EricOfficer | 3K | $214K | 0.003% | 2026-01-09 | Fidelity Brokerage Services LLC |
| 2026-01-09 | Boulding Mark ElliottOfficer | 2K | $180K | 0.003% | 2026-01-09 | Fidelity Brokerage Services LLC |
| 2026-01-08 | Pauwels EricOfficer | 3K | $241K | 0.004% | 2026-01-08 | Fidelity Brokerage Services LLC |
| 2026-01-08 | Pauwels EricOfficer | 1K | $111K | 0.002% | 2026-01-08 | Fidelity Brokerage Services LLC |
| 2026-01-08 | Utter Christine MarieOfficer | 1K | $79K | 0.001% | 2026-01-08 | Fidelity Brokerage Services LLC |
| 2026-01-08 | Klein Matthew B.Officer, Director | 3K | $192K | 0.003% | 2026-01-08 | Fidelity Brokerage Services LLC |
| 2026-01-08 | Golden Lee ScottOfficer | 866 | $66K | 0.001% | 2026-01-08 | Fidelity Brokerage Services LLC |
| 2026-01-08 | Boulding Mark ElliottOfficer | 1K | $98K | 0.002% | 2026-01-08 | Fidelity Brokerage Services LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON5 holders report 5% or more of PTCT in their latest filing, all on Schedule 13G (passive). The largest reported stake is BlackRock, Inc. at 14.8% of the class (11,904,696 shares), filed 2025-12-04 for an event on 2025-11-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-05-15 | 13G/Ano. 1 | JANUS HENDERSON GROUP PLCparent holding company | 7.2M | 8.7% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | The Toronto-Dominion Banknon-US institution | 3.0M | 3.7% | 2026-03-31 |
| 2026-04-30 | 13G | Vanguard Capital Managementinvestment adviser | 4.3M | 5.2% | 2026-03-31 |
| 2026-04-29 | 13G | Vanguard Portfolio Managementinvestment adviser | 4.9M | 5.9% | 2026-03-31 |
| 2026-03-27 | 13G/Ano. 11 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-10 | 13G/Ano. 7 | Wellington Management Group LLPparent holding company | 3.9M | 4.8% | 2025-12-31 |
| 2026-02-10 | 13G/Ano. 7 | Wellington Group Holdings LLPparent holding company | 3.9M | 4.8% | 2025-12-31 |
| 2026-02-10 | 13G/Ano. 7 | Wellington Investment Advisors Holdings LLPparent holding company | 3.9M | 4.8% | 2025-12-31 |
| 2026-02-09 | 13G | STATE STREET CORPORATIONparent holding company | 4.2M | 5.2% | 2025-12-31 |
| 2025-12-04 | 13G/Ano. 12 | BlackRock, Inc.parent holding company | 11.9M | 14.8% | 2025-11-30 |
| 2025-11-14 | 13G/Ano. 5 | Armistice Capital, LLCinvestment adviser, other entity | 3.3M | 4.1% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 5 | Steven Boydparent holding company, individual | 3.3M | 4.1% | 2025-09-30 |
13F holders
Tracked managers holding PTCT at their latest 13F. JSON7 of the 30 tracked managers held PTCT at their latest 13F, $281.4M in total at quarter-end prices. D. E. Shaw & Co. is the largest at $126.3M (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 4 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| D. E. Shaw & Co. | 2026-06-30 | 1.5M | $126.3M | 0.06% | -91K |
| Citadel Advisors | 2026-06-30 | 748K | $61.0M | 0.01% | +363K |
| Renaissance Technologies | 2026-06-30 | 724K | $59.0M | 0.08% | +190K |
| AQR Capital Management | 2026-06-30 | 332K | $27.1M | 0.01% | -10K |
| Millennium Management | 2026-06-30 | 46K | $3.8M | 0.00% | new |
| Fisher Asset Management | 2026-06-30 | 41K | $3.3M | 0.00% | -4K |
| Two Sigma Investments | 2026-06-30 | 11K | $869K | 0.00% | -16K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) PTC Therapeutics reported revenue of $360.5M, up 101.5% from the same quarter a year earlier, and net income of $83.5M (0.92 diluted EPS). In FY 2025 it generated $711.2M of operating cash flow. As of 2026-06-30, cash was $1.05B against $535.5M of debt.
- Cash
- $1.05B
- Debt
- $535.5M
- Equity
- -$165.4M
- Total assets
- $3.25B
- Shares outstanding
- 83,460,802
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $360.5M | $83.5M | 23.2% | 0.92 |
| Q1 FY 2026 | 2026-03-31 | $272.6M | -$2.8M | -1.0% | -0.03 |
| Q4 FY 2025derived | 2025-12-31 | $164.7M | -$135.0M | -82.0% | n/a |
| Q3 FY 2025 | 2025-09-30 | $211.0M | $15.9M | 7.5% | 0.20 |
| Q2 FY 2025 | 2025-06-30 | $178.9M | -$64.8M | -36.3% | -0.83 |
| Q1 FY 2025 | 2025-03-31 | $1.18B | $866.6M | 73.7% | 10.04 |
| Q4 FY 2024derived | 2024-12-31 | $213.2M | -$65.9M | -30.9% | n/a |
| Q3 FY 2024 | 2024-09-30 | $196.8M | -$106.7M | -54.2% | -1.39 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $1.73B | $682.6M | $711.2M | $8.9M | n/a | n/a |
| FY 2024 | 2024-12-31 | $806.8M | -$363.3M | -$107.7M | $6.5M | n/a | n/a |
| FY 2023 | 2023-12-31 | $937.8M | -$626.6M | -$158.4M | $28.4M | n/a | n/a |
| FY 2022 | 2022-12-31 | $698.8M | -$559.0M | -$356.7M | $32.0M | n/a | n/a |
| FY 2021 | 2021-12-31 | $538.6M | -$523.9M | -$251.3M | $28.2M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-29 from the cover page.
What this page is
PTC Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows PTC Therapeutics (PTCT), SEC CIK 1070081, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-28.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-21.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-10-09.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-05-15.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-07-30.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-14.JSON and CSV
- Company record
- EDGAR filing index for CIK 1070081Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
Datasets
Frequently Asked Questions
How much of PTCT is sold short?
8,303,282 shares were held short at the 2026-10-15 settlement, 7.6 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is PTCT's daily short volume?
On 2026-10-28, 148,965 of the 340,669 PTCT shares reported to FINRA were sold short, 43.7% of the day's reported volume. Short volume is a flow for one day, not a position.
Does PTCT have fails to deliver?
The SEC's latest file shows 688 PTCT shares failed to deliver at settlement 2026-09-21. Fails are reported per settlement date and published twice a month with a lag.
Are PTCT insiders buying or selling?
Insiders at PTCT reported 27 open-market sells worth $8.5M in the last 90 days and no open-market buys. Latest filing: SCHMERTZLER MICHAEL (Director) on 2026-10-14.
Have PTCT insiders filed to sell?
50 Form 144 notices on file for PTCT worth $28.3M at the prices reported; 6 in the last 90 days worth $1.8M. Latest: Boulding Mark Elliott filed on 2026-10-09 to sell 192 shares ($12K) from 2026-10-09.
Who owns 5% or more of PTCT?
5 holders report 5% or more of PTCT in their latest filing, all on Schedule 13G (passive). The largest reported stake is BlackRock, Inc. at 14.8% of the class (11,904,696 shares), filed 2025-12-04 for an event on 2025-11-30.
What did PTCT report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) PTC Therapeutics reported revenue of $360.5M, up 101.5% from the same quarter a year earlier, and net income of $83.5M (0.92 diluted EPS). In FY 2025 it generated $711.2M of operating cash flow. As of 2026-06-30, cash was $1.05B against $535.5M of debt.
Which tracked 13F managers own PTCT?
7 of the 30 tracked 13F managers held PTCT shares at their latest filing, $281.4M in all. The largest: D. E. Shaw & Co. (1.5M shares, $126.3M), Ken Griffin's Citadel Advisors (748K shares, $61.0M), Renaissance Technologies (724K shares, $59.0M), Cliff Asness's AQR Capital Management (332K shares, $27.1M), Izzy Englander's Millennium Management (46K shares, $3.8M), Ken Fisher's Fisher Asset Management (41K shares, $3.3M). The table above lists all 7.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.